← Back to catalogue
Hokapi™ Prolactin
EUDAMEDClass B (EU MDR)
Ref 010403001Ref 010403601Ref 010403401Ref 010403101
Identity
- Trade Name
- HOKAPI™ PROLACTIN EUDAMED
- Device Name
- HOKAPI™ PROLACTIN EUDAMED
- Model / Reference
- 010403001 EUDAMED010403601 EUDAMED010403401 EUDAMED010403101 EUDAMED
Identifiers
- Primary DI / UDI-DI
- 06939716404939 EUDAMED06939716404946 EUDAMED06971390434932 EUDAMED06971390434949 EUDAMED
- Basic UDI-DI
- 69713904304037U EUDAMED
- Direct Marketing DI
- 06939716404939 EUDAMED06939716404946 EUDAMED06971390434932 EUDAMED06971390434949 EUDAMED
- EMDN Code
- W0102050108 PROLACTIN EUDAMED
Classification
- Device Class
- Class B EUDAMED
- Market of Registration
- France EUDAMED
Clinical & Handling
Sterile
No
EUDAMED
Human Tissues
No
EUDAMED
Animal Tissues
Yes
EUDAMED
Microbial Substances
No
EUDAMED
Reagent
Yes
EUDAMED
Self Testing
No
EUDAMED
Near-Patient Testing
No
EUDAMED
Professional Testing
Yes
EUDAMED
Companion Diagnostics
No
EUDAMED
Surgical Instrument
No
EUDAMED
New Device
No
EUDAMED
Hokapi™ Prolactin by Suzhou Hokapi Biomedical Engineering Co., Ltd.. — Class B — IVDR — listed in EUDAMED — regulatory data on deviCERTS
Authorization Coverage (European Union — 27 member states)
Regulatory Authorizations
European Union Active
CE/IVDR
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| EUDAMED | European Union | CE/IVDR | 69713904304037U | Class B | Active |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Suzhou Hokapi Biomedical Engineering Co., Ltd..
- EUDAMED SRN
- CN-MF-000013723
- Authorised Representative
- Shanghai International Holding Corp. GmbH(Europe) DE-AR-000000001
Sources (4)
- EUDAMED f41daff1-35fd-4803-b3f0-cf43fcb9d10c 61 fields · synced Jul 29, 2026
- EUDAMED b41bcf49-d3fc-4c44-81b1-e613e43775b3 61 fields · synced May 18, 2026
- EUDAMED 4d0e84a3-47d8-40a8-8c97-474140d38e88 61 fields · synced May 18, 2026
- EUDAMED be2a5490-aeeb-4432-b949-ef58d458c326 61 fields · synced May 18, 2026